Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology

Long-Term Monitoring & Living with Aceruloplasminemia

At a Glance

Long-term aceruloplasminemia care combines individualized blood tests, liver and brain MRI, safety checks for iron-removing medicines, eye and neurological exams, and rehabilitation. Report new choking, falls, infection signs, or severe fatigue promptly.

Living with a multi-system condition like aceruloplasminemia requires a proactive, “eyes-wide-open” approach to health. Because iron can affect your blood, brain, liver, eyes, and pancreas, your care is not a single event but a lifelong rhythm of monitoring and adjustment [1][2].

Your Surveillance Schedule

While there is no single “official” calendar that fits everyone, specialists might suggest individualized components like the following to track disease progression and treatment safety [3][4].

1. Blood Work and Lab Monitoring

  • Complete Blood Count (CBC) and Iron Panel: Frequently used to monitor for worsening anemia, especially when starting or changing the dose of an iron chelator [5][2].
  • Diabetes Screening: Your blood sugar must be monitored to ensure your pancreas is functioning well. Important: Standard HbA1c testing can be distorted by microcytic anemia and changes in red cell lifespan. Your endocrinologist may need to interpret HbA1c alongside Continuous Glucose Monitoring (CGM) or fructosamine tests to ensure you are accurately treated [2][1].
  • Chelation Safety:
    • If taking deferasirox, you will need monthly checks of your kidney function (creatinine) and liver enzymes (ALT/AST) [6][7].
    • If taking deferiprone, weekly blood counts are required to monitor your Absolute Neutrophil Count (ANC), as this drug can rarely cause a dangerous drop in white blood cells [8][9].

2. Advanced Imaging

  • Liver MRI: This estimates hepatic iron, which helps track whether systemic chelation is working. It does not measure total-body or brain iron. It is often performed at baseline and then periodically (e.g., every 1–2 years) depending on your treatment plan [10][4].
  • Brain MRI: Using iron-sensitive sequences like R2* or QSM (if available), doctors can track iron in the thalami and basal ganglia [11][12]. While intervals vary heavily by specialist, these might be repeated periodically to monitor for neurological changes [13].

3. Specialty Check-ins

  • Ophthalmology: Routine multimodal eye exams are suggested. Ensure your eye doctor uses fundus autofluorescence, which can find early iron-related retinal damage that a standard visual acuity test might miss [14][15].
  • Neurology: Regular visits with a movement disorder specialist help track balance, coordination, and speech. These visits are essential for catching the early signs of ataxia or dystonia [16][17].

To manage logistics, consider creating a care-plan template with columns for: Test, Purpose, Who Orders It, and Frequency set by your team. If you struggle with weekly ANC tests or specialty medications, ask your clinic to connect you with a social worker for assistance.

Functional Management: Staying Active

Managing aceruloplasminemia is not just about labs; it’s about maintaining your quality of life. Involving rehabilitation specialists early—even before symptoms are severe—can help you stay functional for longer [18][17].

  • Physical Therapy (PT): Focuses on balance training and “gait safety” to prevent falls. If you experience ataxia (clumsiness), a physical therapist can help you find the right exercises or assistive devices to keep you mobile [17][19].
  • Speech and Language Pathology (SLP): If you notice your speech becoming slurred (dysarthria) or have trouble swallowing (dysphagia), you need a formal swallow assessment. Do not try swallowing exercises on your own; a clinician must arrange personalized aspiration precautions to ensure you eat safely [17][20].
  • Occupational Therapy (OT): Helps you adapt your home and daily routines as your coordination changes, ensuring you can remain independent for as long as possible [20].

The Psychological Journey

Living with a rare, progressive disease carries a heavy emotional weight. It is normal to feel a sense of “scan anxiety” before MRIs or frustration with the frequent blood draws [16].

Psychiatric and cognitive symptoms—such as anxiety, depression, and mood changes—have been reported in many patients and should be carefully assessed [16][21]. Addressing these with a counselor or psychiatrist is just as important as managing your iron levels. You are not just managing a set of lab results; you are navigating a complex life journey that deserves both medical and emotional support.

When to Call Your Team

Between scheduled visits, watch for “triggers” that might suggest a need for an earlier check-in:

  • New or worsening choking episodes during meals [19].
  • A sudden increase in falls or loss of balance [17].
  • Fever or signs of infection (especially if you are on deferiprone) [8].
  • Extreme fatigue that interferes with your daily life, which may signal a drop in hemoglobin [5].

Common questions in this guide

How often should I have follow-up testing for aceruloplasminemia?
There is no single schedule for everyone with aceruloplasminemia. Your team may use regular blood tests, periodic liver MRI, brain MRI at an individualized interval, and routine specialty visits. Testing may become more frequent when a medicine is started or its dose changes.
Which blood tests are important in aceruloplasminemia?
A complete blood count and iron panel help track anemia and iron status, while glucose monitoring helps assess pancreatic function. HbA1c may be less reliable with microcytic anemia or altered red-cell lifespan, so clinicians may also use continuous glucose monitoring or fructosamine. Deferasirox generally requires monthly kidney and liver checks, while deferiprone requires weekly white-blood-cell monitoring.
How do MRI scans help monitor aceruloplasminemia?
Liver MRI estimates liver iron and helps show whether iron-removing treatment is working, but it does not measure total-body or brain iron. Brain MRI using R2* or QSM sequences can track iron in areas such as the thalamus and basal ganglia. Specialists decide when to repeat each scan.
Which specialists are involved in long-term aceruloplasminemia care?
Care may include hematology, neurology, endocrinology, ophthalmology, and rehabilitation professionals, with mental-health support when needed. Eye examinations may include fundus autofluorescence, and movement-disorder visits can monitor balance, coordination, and speech.
Can rehabilitation therapy help me stay independent with aceruloplasminemia?
Physical therapy can address balance and walking safety, speech-language pathology can assess swallowing and speech, and occupational therapy can help adapt daily routines and the home. A formal swallow assessment is important if swallowing trouble or choking develops; do not start swallowing exercises without clinical guidance.
What symptoms should prompt an earlier call to my care team?
Contact your team sooner for new or worsening choking, a sudden increase in falls or loss of balance, fever or infection signs while taking deferiprone, or extreme fatigue that disrupts daily activities. These changes can signal swallowing risk, infection, or a blood-count problem and should be assessed rather than managed alone.
How can I get support for the emotional strain of aceruloplasminemia monitoring?
Anxiety before scans, frustration with repeated blood tests, depression, and mood changes deserve attention as part of your care. A counselor or psychiatrist can help assess symptoms and support coping with the ongoing medical routine.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current iron levels and symptoms, what is the 'ideal' schedule for my blood work (CBC, ferritin, and HbA1c)?
  2. 2.Can we establish a baseline for my liver and brain iron using R2* or QSM MRI, and how often should these be repeated?
  3. 3.What is our specific plan for monitoring my kidney and liver function while I am on chelation therapy?
  4. 4.If I am taking deferiprone, how will we coordinate my weekly white blood cell (ANC) checks?
  5. 5.At what point should I begin proactive physical or speech therapy to stay ahead of neurological changes?
  6. 6.Who is the lead 'coordinator' on my multidisciplinary team to ensure all these different specialists are sharing my results?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    A novel ceruloplasmin mutation identified in a Chinese patient and clinical spectrum of aceruloplasminemia patients.

    Xu WQ, Ni W, Wang RM, et al.

    Metabolic brain disease 2021; (36(8)):2273-2281 doi:10.1007/s11011-021-00799-0.

    PMID: 34347207
  2. 2

    Aceruloplasminemia presents as Type 1 diabetes in non-obese adults: a detailed case series.

    Vroegindeweij LH, van der Beek EH, Boon AJ, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2015; (32(8)):993-1000 doi:10.1111/dme.12712.

    PMID: 25661792
  3. 3

    New mutation of the ceruloplasmin gene in the case of a neurologically asymptomatic patient with microcytic anaemia, obesity and supposed Wilson's disease.

    Ondrejkovičová M, Dražilová S, Drakulová M, et al.

    BMC gastroenterology 2020; (20(1)):95 doi:10.1186/s12876-020-01237-8.

    PMID: 32264837
  4. 4

    [Aceruloplasminemia, a rare condition not to be overlooked].

    Lobbes H, Reynaud Q, Mainbourg S, et al.

    La Revue de medecine interne 2020; (41(11)):769-775 doi:10.1016/j.revmed.2020.06.002.

    PMID: 32682623
  5. 5

    Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia.

    Pelucchi S, Mariani R, Ravasi G, et al.

    Parkinsonism & related disorders 2018; (51()):36-42 doi:10.1016/j.parkreldis.2018.02.036.

    PMID: 29503155
  6. 6

    Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles.

    Yassin MA, Soliman AT, De Sanctis V, et al.

    Mediterranean journal of hematology and infectious diseases 2018; (10(1)):e2018064 doi:10.4084/MJHID.2018.064.

    PMID: 30416696
  7. 7

    The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation.

    Bayhan T, Ünal Ş, Ünlü O, et al.

    Hematology (Amsterdam, Netherlands) 2017; (22(4)):248-251 doi:10.1080/10245332.2016.1252004.

    PMID: 27809710
  8. 8

    Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.

    Saliba AN, El Rassi F, Taher AT

    Expert review of hematology 2016; (9(2)):151-68 doi:10.1586/17474086.2016.1126176.

    PMID: 26613264
  9. 9

    Deferiprone-induced agranulocytosis: 20 years of clinical observations.

    Tricta F, Uetrecht J, Galanello R, et al.

    American journal of hematology 2016; (91(10)):1026-31 doi:10.1002/ajh.24479.

    PMID: 27415835
  10. 10

    Diagnosing aceruloplasminemia: navigating through red herrings.

    Kharel Z, Kharel H, Phatak PD

    Annals of hematology 2024; (103(6)):2173-2176 doi:10.1007/s00277-024-05743-7.

    PMID: 38637332
  11. 11

    MR imaging for the quantitative assessment of brain iron in aceruloplasminemia: A postmortem validation study.

    Vroegindeweij LHP, Wielopolski PA, Boon AJW, et al.

    NeuroImage 2021; (245()):118752 doi:10.1016/j.neuroimage.2021.118752.

    PMID: 34823024
  12. 12

    MRI R2* and quantitative susceptibility mapping in brain tissue with extreme iron overload.

    Birkl C, Panzer M, Kames C, et al.

    European radiology experimental 2025; (9(1)):80 doi:10.1186/s41747-025-00622-w.

    PMID: 40848176
  13. 13

    Aceruloplasminemia: a multimodal imaging study in an Italian family with a novel mutation.

    Salsone M, Arabia G, Annesi G, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(3)):1791-1797 doi:10.1007/s10072-021-05613-4.

    PMID: 34559338
  14. 14

    ASYMPTOMATIC OCULAR MANIFESTATIONS OF ACERULOPLASMINEMIA IN TWO ADULT WHITE SIBLINGS: A MULTIMODAL IMAGING APPROACH.

    Furashova O, Mielke S, Lindner U

    Retinal cases & brief reports 2023; (17(3)):273-278 doi:10.1097/ICB.0000000000001166.

    PMID: 34014900
  15. 15

    ABSENCE OF MACULAR DEGENERATION IN A PATIENT WITH ACERULOPLASMINEMIA.

    Ronquillo CC, Sauer L, Morgan D, et al.

    Retina (Philadelphia, Pa.) 2019; (39(9)):1824-1828 doi:10.1097/IAE.0000000000002628.

    PMID: 31356495
  16. 16

    New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients.

    Vroegindeweij LHP, Langendonk JG, Langeveld M, et al.

    Parkinsonism & related disorders 2017; (36()):33-40 doi:10.1016/j.parkreldis.2016.12.010.

    PMID: 28012953
  17. 17

    Deferasirox Might Be Effective for Microcytic Anemia and Neurological Symptoms Associated with Aceruloplasminemia: A Case Report and Review of the Literature.

    Miyake Z, Nakamagoe K, Yoshida K, et al.

    Internal medicine (Tokyo, Japan) 2020; (59(14)):1755-1761 doi:10.2169/internalmedicine.4178-19.

    PMID: 32238721
  18. 18

    Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.

    Vroegindeweij LHP, Boon AJW, Wilson JHP, Langendonk JG

    Orphanet journal of rare diseases 2020; (15(1)):105 doi:10.1186/s13023-020-01385-w.

    PMID: 32334607
  19. 19

    Neurodegeneration With Brain Iron Accumulation in a Case of Adult Aceruloplasminemia.

    Maarad N, Rahmani M, Taho A, et al.

    Cureus 2024; (16(8)):e67331 doi:10.7759/cureus.67331.

    PMID: 39165621
  20. 20

    Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments.

    Schneider SA, Garg D, Iankova V, Klopstock T

    Movement disorders clinical practice 2026; doi:10.1002/mdc3.70736.

    PMID: 42429179
  21. 21

    Novel ceruloplasmin gene mutation causing aceruloplasminemia with diabetes in a Chinese woman: a case report.

    Xiao Y, Zhu C, Jiang F, et al.

    Annals of palliative medicine 2022; (11(7)):2516-2522 doi:10.21037/apm-21-1086.

    PMID: 34670377

This page is for informational purposes only and does not constitute medical advice. Your specialists should set your aceruloplasminemia monitoring, medication-safety checks, and rehabilitation plan.

Get notified when new evidence is published on Aceruloplasminemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.